Canaccord Genuity Reaffirms Buy Rating for KemPharm, Inc. (KMPH)
Canaccord Genuity restated their buy rating on shares of KemPharm, Inc. (NASDAQ:KMPH) in a research note released on Monday morning. The firm currently has a $7.00 price target on the specialty pharmaceutical company’s stock.
Several other research analysts also recently commented on KMPH. Oppenheimer Holdings, Inc. set a $13.00 price target on shares of KemPharm and gave the company a buy rating in a report on Thursday, August 10th. ValuEngine downgraded shares of KemPharm from a sell rating to a strong sell rating in a report on Saturday, July 8th. Royal Bank Of Canada restated a buy rating and set a $8.00 price objective on shares of KemPharm in a research report on Monday, May 15th. Zacks Investment Research upgraded shares of KemPharm from a sell rating to a hold rating in a research report on Wednesday, July 12th. Finally, Roth Capital began coverage on shares of KemPharm in a research report on Wednesday, June 28th. They set a buy rating and a $8.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of Buy and an average price target of $8.10.
KemPharm (KMPH) opened at 3.30 on Monday. The firm’s market capitalization is $48.37 million. The stock’s 50 day moving average is $3.07 and its 200 day moving average is $3.81. KemPharm has a one year low of $2.45 and a one year high of $5.40.
KemPharm (NASDAQ:KMPH) last announced its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.19. On average, equities research analysts predict that KemPharm will post ($2.72) earnings per share for the current fiscal year.
In related news, CEO Travis C. Mickle acquired 8,000 shares of the stock in a transaction dated Tuesday, June 20th. The shares were purchased at an average price of $3.45 per share, for a total transaction of $27,600.00. Following the transaction, the chief executive officer now owns 1,629,612 shares in the company, valued at approximately $5,622,161.40. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have bought 17,275 shares of company stock worth $51,808. Corporate insiders own 22.80% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. C WorldWide Group Holding A S raised its position in shares of KemPharm by 110.1% during the 2nd quarter. C WorldWide Group Holding A S now owns 381,699 shares of the specialty pharmaceutical company’s stock valued at $1,527,000 after buying an additional 200,000 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in shares of KemPharm during the 1st quarter valued at $647,000. Finally, Bank of New York Mellon Corp raised its position in shares of KemPharm by 17.6% during the 1st quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock valued at $112,000 after buying an additional 3,414 shares in the last quarter. Hedge funds and other institutional investors own 40.01% of the company’s stock.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.